TGTX
TG Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.58B
P/E Ratio
17.31
EPS
$2.86
Beta
1.68
52W High
$50.39
52W Low
$25.28
50-Day MA
$38.32
200-Day MA
$33.20
Dividend Yield
—
Profit Margin
65.90%
Forward P/E
38.02
PEG Ratio
1.61
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $700.35M |
| Gross Profit (TTM) | $581.67M |
| EBITDA | $149.58M |
| Operating Margin | 17.00% |
| Return on Equity | 112.60% |
| Return on Assets | 8.55% |
| Revenue/Share (TTM) | $4.87 |
| Book Value | $4.11 |
| Price-to-Book | 13.00 |
| Price-to-Sales (TTM) | 10.82 |
| EV/Revenue | 11.17 |
| EV/EBITDA | 52.07 |
| Quarterly Earnings Growth (YoY) | 300.00% |
| Quarterly Revenue Growth (YoY) | 69.60% |
| Shares Outstanding | $153.08M |
| Float | $135.10M |
| % Insiders | 7.47% |
| % Institutions | 70.24% |
Historical Volatility
HV 10-Day
59.55%
HV 20-Day
52.18%
HV 30-Day
63.27%
HV 60-Day
52.81%
HV Rank
87.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($48.00 target)
1
Strong Buy6
Buy1
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026